Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) is a publicly traded holding company that initiates strategic investments in leading edge medical technologies. Its subsidiary, Estracure, Inc. is currently developing a next-generation coronary stent based on proprietary estrogen-based technologies which may minimize restenosis and potentially prevent progression of coronary lesions. Based on the results of a multi-center Phase II “proof-of-concept” trial in humans and ongoing pig trials, Phase II/III trials with the proprietary 17-beta-estradiol, stent and polymer combination are being currently planned for patient accrual later this year. Duravest also has a controlling interest in Bio-Magnetic Therapy Systems, Inc. (BMTS), a leading German-US medical technology firm dedicated to the safe, non-invasive treatment of osteoarthritis, osteoporosis and orthopedic injuries. Its proprietary, patented devices are already used clinically in Germany while further expansion is planned for European, Asian and U.S. markets.

Full news